Why Retatrutide is generating global attention

In the rapidly evolving field of medical obesity treatment, few investigational drugs have generated as much discussion as retatrutide. Although not yet approved in Ireland, search interest is rising quickly. Patients are increasingly asking:

• What is retatrutide?
• How much weight loss does it cause?
• Is it better than Wegovy?
• Is it stronger than Mounjaro?
• When will it be available in Ireland?
• Should I wait for it?

Retatrutide represents a potential next-generation obesity therapy targeting multiple hormonal pathways involved in appetite regulation, metabolism, and energy expenditure.

However, it remains investigational. Understanding what it is and what it is not is essential before drawing conclusions.

What Is Retatrutide?

Retatrutide is an investigational medication developed by Eli Lilly and Company. It is described as a triple hormone receptor agonist, meaning it activates:

• GLP-1 receptors
• GIP receptors
• Glucagon receptors

This differentiates it from currently approved therapies such as:

• Wegovy (GLP-1 only)
• Mounjaro (GLP-1 + GIP)

Retatrutide adds glucagon receptor activation, creating a triple-pathway metabolic effect.

Understanding the triple mechanism

GLP-1 Activation

• Reduces appetite
• Increases satiety
• Slows gastric emptying
• Improves insulin secretion

This pathway is responsible for the success of semaglutide-based therapies.

GIP Activation

• Enhances insulin sensitivity
• Supports metabolic flexibility
• Influences fat metabolism

This pathway enhances metabolic efficiency.

Glucagon Activation

• Increases energy expenditure
• Promotes fat oxidation
• Stimulates thermogenesis
• Mobilises stored energy

In isolation, glucagon can increase blood glucose. However, when balanced with GLP-1 and GIP activation, the overall effect may favour fat loss while maintaining glycaemic control.

The theory behind retatrutide is simple but powerful:

Reduce calorie intake and increase calorie expenditure simultaneously.

Retatrutide clinical trial results

Retatrutide completed a large Phase 2 randomised, double-blind, placebo-controlled trial in adults with obesity or overweight.

Trial design highlights

• Participants: Adults with BMI ≥30, or ≥27 with weight-related conditions
• Duration: 48 weeks
• Weekly injection
• Dose-ranging study (multiple escalating doses)
• Placebo comparison arm

Headline results

At the highest dose studied:

• Mean weight loss approached 24% at 48 weeks
• Many participants lost ≥20%
• Some individuals approached 25% reduction

For context:

• Semaglutide: ~15%
• Tirzepatide: ~20–22%
• Retatrutide (Phase 2): ~24%

These results approach the lower range of bariatric surgical outcomes. However, Phase 2 results are not definitive evidence of approval. Phase 3 confirmation is required.

Dose-response findings

The trial demonstrated a clear dose-response relationship.

• Lower doses produced moderate weight loss
• Higher doses produced substantially greater reductions
• Weight loss increased progressively over time
• A plateau had not clearly been reached at week 48

This suggests potential for continued weight reduction beyond one year, though long-term data remains under investigation.

Metabolic and cardiometabolic outcomes

Beyond weight loss, retatrutide was associated with improvements in:

• HbA1c
• Fasting glucose
• Triglycerides
• LDL cholesterol
• Liver fat markers
• Waist circumference

These metabolic improvements reinforce that obesity treatment is about cardiometabolic health — not cosmetic weight loss.

Discontinuation and tolerability

As with other incretin-based therapies, gastrointestinal side effects were common.

Reported side effects included:

• Nausea
• Vomiting
• Diarrhoea
• Constipation

Higher doses were associated with increased side effects.

Some participants discontinued therapy due to tolerability issues.

Dose escalation and gradual titration remain important components of safe prescribing.

Safety considerations

Retatrutide’s safety profile in Phase 2 trials was broadly similar to other GLP-1–based medications.

However, because of glucagon receptor activation, monitoring includes:

• Resting heart rate
• Blood pressure
• Glycaemic response
• Metabolic markers

Mild increases in heart rate were observed.

Long-term cardiovascular outcome trials are ongoing.

Unlike semaglutide, which has established cardiovascular benefit data, retatrutide’s long-term cardiovascular profile remains under study.

Is retatrutide approved in Ireland?

No, retatrutide is not licensed in Ireland and has not received authorisation from the Health Products Regulatory Authority. It is not legally available via prescription and should not be purchased online

When could Retatrutide become available?

Retatrutide is currently in Phase 3 trials.

Approval would require:

1. Completion of Phase 3 studies
2. Submission to European regulators
3. EMA review
4. National authorisation
5. Manufacturing scale-up

There is no confirmed launch date for Ireland. Even under optimistic timelines, widespread availability is unlikely in the immediate future.

What if Phase 3 Results differ?

Phase 3 trials involve:

• Larger populations
• Longer duration
• Broader safety monitoring
• Rare adverse event detection

It is possible that:

• Efficacy is confirmed
• Efficacy is slightly lower
• Safety signals emerge
• Dose adjustments are required

This is why regulatory approval depends on Phase 3 outcomes.

Obesity in Ireland: why this matters

Approximately 60% of adults in Ireland are overweight or obese. Around 1 in 4 adults meet obesity criteria.

Obesity contributes significantly to:

• Type 2 diabetes
• Cardiovascular disease
• Hypertension
• Stroke
• Fatty liver disease

Ireland’s healthcare strategy increasingly recognises obesity as a chronic disease requiring long-term management.

Advanced pharmacotherapy is becoming part of that conversation.

What you can do now

If you are researching retatrutide, it likely means you are seeking significant, sustained weight loss. While retatrutide remains investigational, licensed treatments are available today in Ireland under medical supervision.

A clinical consultation can assess:

• BMI eligibility
• Medical history
• Cardiometabolic risk
• Suitability
• The most appropriate approved therapy

Start Your Consultation Today

You do not need to wait for investigational therapies to begin evidence-based treatment. If you meet eligibility criteria, you can explore regulated, licensed options now.

Start your online consultation for medically supervised weight management.